PMID: 8950525Sep 1, 1996Paper

Tentative interpretive criteria for testing the susceptibility of Streptococcus pneumoniae to eight fluoroquinolones

Diagnostic Microbiology and Infectious Disease
P C FuchsS D Brown

Abstract

Broth microdilution and disk diffusion methods were used to test ciprofloxacin, clinafloxacin, fleroxacin, grepafloxacin, ofloxacin, PD131628, sparfloxacin, and trovafloxacin against Streptococcus pneumoniae isolates. With each fluroquinolone tested, there was a striking unimodal population. With the exception of fleroxacin, over 96% of pneumococci tested were inhibited by each drug's modal MIC +/-1 twofold concentration. Over 92% of pneumococci produced inhibitory zone diameters equal to the mode +/-4 mm for each drug. For most fluoroquinolones, the interpretive criteria approved or proposed for nonfastidious organisms appear to be appropriate for pneumococci. For clinafloxacin and trovafloxacin, however, the proposed MIC breakpoints for nonfastidious organisms are four-to eightfold greater than the highest MIC encountered with pneumococci. For future surveillance efforts, low concentrations must be evaluated to detect any subtle shift in pneumococcal populations that might be undetected by testing only breakpoint concentrations.

References

May 1, 1992·Diagnostic Microbiology and Infectious Disease·R N JonesM S Barrett
Mar 1, 1994·Diagnostic Microbiology and Infectious Disease·K WaitesK Halkias
Jun 1, 1994·The Journal of Antimicrobial Chemotherapy·P C FuchsM A Pfaller
Jul 1, 1996·The Journal of Antimicrobial Chemotherapy·A L Barry, P C Fuchs
Aug 1, 1996·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·P C FuchsD L Sewell

❮ Previous
Next ❯

Citations

Oct 3, 1998·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·J C Pechère, T D Gootz
May 9, 1998·International Journal of Antimicrobial Agents·K WaitesE Swiatlo
May 2, 2001·Journal of Chemotherapy·E M MokaddasS C Sanyal
Mar 1, 2002·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·Michael S. Marriott

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Related Papers

European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology
A P JohnsonT Parsons
The Journal of Antimicrobial Chemotherapy
R Wise, J M Andrews
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology
H S SaderR N Jones
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
Sanford Chodosh
© 2021 Meta ULC. All rights reserved